Novian Health

Novian Health, a leading company in image-guided laser tumor therapy, is a late-stage development medical device company based in Chicago, with a subsidiary, Novian Health SAS, in France. The company has pioneered Novilase, a minimally invasive alternative to lumpectomy for the treatment of breast tumors using Interstitial Laser Therapy (ILT). Novilase has received a CE Mark for focal destruction of malignant and benign breast tumors, making it the first thermal ablation device to be approved for breast cancer. Novian Health's innovative technology enables breast surgeons and radiologists to ablate tumors with image-guided laser therapy, offering significant advantages over surgery, including fewer retreatments, quicker recovery, less pain and fatigue, minimal scarring, and only requiring local anesthesia. The company is set to conduct a multicenter pivotal trial to evaluate Novilase® laser therapy as a treatment for early-stage breast cancer and will seek U.S. market clearance for the focal destruction of malignant tumors. Novian is also planning to begin commercialization in Europe. With U.S. FDA 510(k) clearance for the treatment of fibroadenomas and ablation of soft tissue, Novian Health has initiated a registry to collect additional information on benign breast tumors treated at centers around the U.S. The company recently secured a $5.00M convertible note investment on July 28, 2021, indicating continued financial backing for its innovative medical solutions. Novian Health's commitment to revolutionizing breast tumor treatment makes it a promising investment prospect in the Health Care industry. For more information, visit: www.novianhealth.com and www.novilase.com. Overall, Novian Health's cutting-edge technology and growing recognition from regulatory bodies position it as an attractive investment opportunity in the evolving landscape of medical innovation.